Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.66M | 131.67M | -33.21M | -30.62M | 207.34M |
| Total Depreciation and Amortization | 808.00K | 536.00K | 647.00K | 892.00K | 820.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.52M | 6.33M | 7.33M | 7.28M | 7.74M |
| Change in Net Operating Assets | 124.69M | -167.72M | -2.63M | 291.06M | -243.33M |
| Cash from Operations | 125.36M | -29.18M | -27.86M | 268.62M | -27.43M |
| Capital Expenditure | -545.00K | -310.00K | -775.00K | -28.00K | -242.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -93.86M | -8.42M | -207.94M | -88.09M | 6.31M |
| Cash from Investing | -94.40M | -8.73M | -208.71M | -88.12M | 6.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.92M | 4.03M | 12.05M | 2.57M | 7.80M |
| Repurchase of Common Stock | -479.00K | 0.00 | 0.00 | 0.00 | -600.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11.44M | 4.03M | 12.05M | 2.57M | 7.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 42.40M | -33.87M | -224.52M | 183.08M | -14.16M |